Search results for query: *

Really can’t be bothered, but if finding ‘evidence’ to satisfy yourself that it won’t help tinnitus floats your both then fair enough. For me the fact it has reduced ‘tinnitus’ at all, irrespective of the test cohort being Meniere’s patients, is the best evidence of any drug reducing ‘tinnitus’...

Taking a break from this thread now too until there is new information to post. Why negativity? SPI-1005 is targeting both Meniere's and NIHL. It has reduced tinnitus loudness 30% (treatment group) vs 10% (placebo) in Meniere's trials. This is one of the few trials that has reduced tinnitus...

Look, if you go to their website, you will find they are targeting NIHL and associated tinnitus with SP-1005. This is in addition to Meniere's Disease. Their drug does not working on reducing fluid in the ear. It is a potent anti-inflammatory, not a diuretic.

The compound is a potent anti-inflammatory so it treats inflammation, hence the hope it might help general tinnitus.

The clinical trial is 1 year. Fast track NDA 6 months. Guess is 20-24 months.

30% reduction in tinnitus loudness vs 10% of that in placebo.

Just an interesting find. One of Sound Pharmaceuticals’ advisors is a former Nobel Prize winner for Physiology and Medicine. Wikipedia: Bruce Beutler In fact. Their entire team is quite impressive. Sound Pharmaceuticals' Team This one has ‘fast track’ so 60% chance of getting to market. I...

SPI-1005 for the Treatment of Meniere's Disease (STOPMD-3) Not yet recruiting for Phase 3 Meniere's unfortunately. SPI-1005 Treatment in Moderate COVID-19 Patients Still 'enrolling by invitation' (if you can call moderate and severe COVID-19 an invitation) for COVID-19 trials. Interesting...

Nothing regarding Ebselent for nearly two years. 30% reduction in tinnitus loudness not to be sniffed at. Placebo controlled too. 10% reduction for placebo. Anyone on here taking part in their Meniere's Phase 3 or COVID-19 Phase 2? The company have been so quiet. I suppose it is a ‘private’...